Publications by authors named "D Gustinucci"
Unlabelled: The use of clinically validated human papillomavirus (HPV) assays is recommended in cervical cancer screening, and extended genotyping is getting attention as a triage biomarker because of the different oncogenic risk of the high-risk HPV genotypes. We compared the results of the Becton & Dickinson (BD) Onclarity HPV assay, on the residual baseline cervico-vaginal specimens of the NTCC2 trial, to those of the screening HPV-DNA assay (Cobas 4800 or HC2) and to cytology, p16/ki67 and E6/E7 mRNA triage results. We genotyped virtually all HPV-positive women and a consecutive sample of HPV-negatives.
View Article and Find Full Text PDFArticle Synopsis
- High-risk HPV types have different chances of leading to severe cervical issues, and this study looks at ways to effectively triage HPV-positive women using cytology, dual staining, and extended genotyping.
- The study analyzed samples from over 3,000 women who tested positive for HPV DNA, categorizing them based on risk levels for developing high-grade lesions over 24 months.
- Results suggest that certain groups of women can be monitored with less frequent screenings, while others require immediate follow-up, enhancing the efficiency of cervical cancer prevention strategies.
As the primary screening test, E6/E7 mRNA has shown similar sensitivity for CIN3+ and lower positivity rate than the HPV DNA test. Nevertheless, the overall mRNA positivity is too high for immediate colposcopy, making a triage test necessary. The aim was to estimate the mRNA performance as a primary test with different triage strategies.
View Article and Find Full Text PDFHow to manage human papillomavirus (HPV)-positive women in cervical cancer screening remains debated. Our study compared different strategies to triage HPV positivity in a large cohort of women participating in a population HPV-based screening program. Women were tested for HPV (Cobas 4800; Roche), and those positive were triaged with cytology; cytology-positives were referred to colposcopy, while negatives were referred to 1-year HPV retesting.
View Article and Find Full Text PDFObjective: To evaluate the clinical accuracy of Hepika test to identify cancer/precancerous lesions of the uterine cervix.
Materials And Methods: A multicentre retrospective study was carried out in 2018 and included 330 liquid-based cytology samples from three Italian centres of women aged 25-64 who had been tested for the human papillomavirus (HPV) and whose histology or follow-up outcome was known. Hepika is an enzyme-linked immunosorbent assay (ELISA) targeting the protein complexes E6#p53 and E7#pRb.